Editorial on “Multiple boluses of intravenous tranexamic acid to reduce hidden blood loss after primary total knee arthroplasty without tourniquet: a randomized clinical trial”
Currently, many surgeons use tranexamic acid (TXA) to reduce peri-operative blood loss and the requirements for transfusion without increasing the incidence of vascular thromboembolisms (VTEs) in patients undergoing total knee arthroplasty (TKA). TXA may be given by an intravenous (IV) or topical route (1). However, the optimal dosage, treatment duration, timing of administration, and best administration route all remain unclear. Both effectiveness and safety may be influenced by the dose, number of doses, timing, and route of administration (2); these factors vary greatly in the literature (3).